Monitoring of molecular profiling of allergen-antibody responses in HDM-immunotherapy patients

Figures & data

Table 1. Demographic data of the subjects included in the study – cohort HDM-AIT and HDM non-AIT.

group	HDM-AIT	HDM non-AIT	P
number	63	22
age mean ±SD, y	29 ± 8.8	28.7 ± 9.9	NS
sex (male/female)	30/33	12/10	NS
asthma (%)	34%	22,2%	NS
monovalent sensitization to HDM	33 (52%)	15 (68%)	NS

Legend: NS – not significant.

Table 2. Frequency of sensitization to specific HDM molecules in the study group and the control group.

molecule	group HDM-AIT n = 63	group HDM non -AIT n = 22	p
rDer p 1	44(68.9%)	17 (70.8%)	NS
rDer p 2	51 (81%)	18 (75%)	NS
rDer f 1	42 (66.7%)	14 (58.3%)	NS
rDer f 2	38 (60.3%)	16 (66.6%)	NS
rDer p 10	7 (11.1.1%)	5 (20.8%)	NS
rDer p 11	12 (19%)	9 (37.5%)	NS
rDer p 23	25 (39.7%)	12 (50%)	NS

Legend: Serum levels (ISU) of IgE to D. pteronyssinus and D. farinae allergens have been assessed with positivity threshold set at 0.15 kU/L; NS- not significant.

Figure 1. Number of IgE sensitization to 9 allergens (extracts and molecules) in the whole study population (N = 86).

Legend: Serum levels (ISU) of IgE to D. pteronyssinus and D. farinae allergens were assessed with a positivity threshold set at 0.15 kU/L.

Figure 2. sIge levels against the extract of Dermatophagoides pteronyssinus after 6 and 12 months in the HDM AIT study group.

Figure 3. sIge levels against the extract of Dermatophagoides farinae after 6 and 12 months in the HDM AIT study group.

Figure 4. sIge levels against rDer p 1 after 6 and 12 months in the HDM AIT study group.

Figure 5. sIge levels against rDer p 2 and rD far 2 after 6 and 12 months of HDM AIT (HDM-AIT study group).

Table 3. sIge levels against HDM extract and specific HDM molecules at baseline, after 6 months and after 12 months of study.

a. HDM non-AIT control group
Variable		Specific IgE against particular HDM allergens [kU/L]
		AIT baseline	After 6 months of study	After 12 months of study
D. pteronyssinus [N = 22]	Mean [Min- Max]	7.82 [0.01–50.10]	8.03 [0.01–51.20]	8.57 [0.01–60.40]
	SD	12.47	12.59	14.31
	Median [Q25-Q75]	3.26 [0.18–7.12]	3.84 [0.21–7.12]	3.465 [0.23–8.02]
D. farinae [N = 22]	Mean [Min- Max]	8.27 [0.01–65.40]	8.91 [0.01–66.4]	7.73 [0.01–51.10]
	SD	14.41	15.24	11.80
	Median [Q25-Q75]	3.855 [0.18–8.77]	4.07 [0.66–7.95]	3.935 [0.33–9.22]
rDer p 1 [N = 22]	Mean [Min- Max]	8.07 [0.01–76.80]	7.77 [0.01–70.50]	8.39 [0.01–80.20]
	SD	16.48	15.21	17.165
	Median [Q25-Q75]	2.065 [0.01–9.18]	2.185 [0.01–9.03]	2.155 [0.01–10.10]
rDer p 2 [N = 22]	Mean [Min- Max]	5.00 [0.01–42.70]	4.89 [0.01–43.10]	5.50 [0.01–50.40]
	SD	10.60	9.86	11.29
	Median [Q25-Q75]	0.50 [0.01–5.34]	0.575 [0.01–5.10]	0.655 [0.01–6.01]
rDer p 10 [N = 21]	Mean [Min- Max]	4.24 [0.01–45.10]	4.28 [0.01–46.90]	4.79 [0.01–55.2]
	SD	10.49	10.89	12.50
	Median [Q25-Q75]	0.01 [0.01–1.12]	0.01 [0.01–0.77]	0.01 [0.01–1.22]
rDer p 11 [N = 22]	Mean [Min- Max]	1.32 [0.01–12.60]	1.32 [0.01–12.80]	—————–
	SD	3.21	3.28	——————
	Median [Q25-Q75]	0.01 [0.01–0.19]	0.01 [0.01–0.21]	—————–
rDer p 23 [N = 22]	Mean [Min- Max]	3.33 [0.01–19.21]	3.38 [0.01–20.30]	——————-
	SD	6.17	6.35	—————-
	Median [Q25-Q75]	0.01 [0.01–2.11]	0.01 [0.01–2.15]	—————-
rDer f 1 [N = 22]	Mean [Min- Max]	4.49 [0.01–44.20]	4.63 [0.01–43.20]	4.83 [0.01–46.90]
	SD	9.40	9.22	9.92
	Median [Q25-Q75]	2.12 [0.01–4.70]	2.14 [0.01–5.01]	2.89 [0.01–5.20]
rDer f 2 [N = 22]	Mean [Min- Max]	5.00 [0.01–38.20]	4.94 [0.01–38.10]	5.18 [0.01–40.10]
	SD	9.56	9.46	9.82
	Median [Q25-Q75]	0.51 [0.01–4.10]	0.455 [0.01–4.22]	[0.01–4.33]
b. HDM-AIT study group
Variable		Specific IgE against particular HDM allergens [kU/L]
		AIT baseline [N = 63]	After 6 months of AIT [N = 54]	After 12 months of AIT [N = 53]
Dermatophagoides pteronyssinus	Mean [Min- Max]	15.80 [0.01-134]	16.525 [0.01-133]	13.11 [0.01-122]
	SD	29	30.76	25.38
	Median [Q25-Q75]	4.70 [0.7–15.9]	4.59 [0.55–13.2]	4.20 [0.45–11.2]
Dermatophagoides farinae	Mean [Min- Max]	23.56 [0.01-151]	19.745 [0.01-140]	17.18 [0.01-134]
	SD	40.43	34.66	29.70
	Median [Q25-Q75]	6.90 [0.39–20.1]	5.20 [0.30-17]	4.80 [0.30–15.4]
rDer p 1	Mean [Min- Max]	16.37 [0.01-149]	17.83 [0.01-152]	12.04 [0.01-88]
	SD	32.48	33.70	21.58
	Median [Q25-Q75]	1.10 [0.01–15.09]	1.25 [0.01–17.30]	0.97 [0.01–15.40]
rDer p 2	Mean [Min- Max]	31.34 [0.01-130]	26.91 [0.01-137]	24.14 [0.01-132]
	SD	39.71	35.91	32.86
	Median [Q25-Q75]	14 [0.76-53]	12.25 [0.43–40.1]	9.60 [0.55–37.1]
rDer p 10	Mean [Min- Max]	3.085 [0.01-185]	3.35 [0.01-175]	3.05 [0.01-156]
	SD	23.30	23.80	21.42
	Median [Q25-Q75]	0.01 [0.01–0.01]	0.01 [0.01–0.01]	0.01 [0.01–0.01]
rDer p 11	Mean [Min- Max]	1.46 [0.01-67]	1.55 [0.01-145]	1.00 [0.01-45]
	SD	8.51	28.32	6.19
	Median [Q25-Q75]	0.01 [0.01–0.01]	0.01 [0.01–0.01]	0.01 [0.01–0.01]
rDer p 23	Mean [Min- Max]	10.23 [0.01-191]	9.78 [0.01-145]	9.13 [0.01-132]
	SD	31.35	28.32	25.90
	Median [Q25-Q75]	0.01 [0.01–1.50]	0.01 [0.01–0.60]	0.01 [0.01–0.87]
rDer f 1	Mean [Min- Max]	13.71 [0.01-164]	14.97 [0.01-166]	14.72 [0.01-145]
	SD	30.62	32.60	30.64
	Median [Q25-Q75]	1.21 [0.01-12]	1.325 [0.01–11.20]	1.09 [0.01–12.90]
rDer f 2	Mean [Min- Max]	17.12 [0.01-182]	16.49 [0.01–154.20]	14.81 [0.01-112]
	SD	37.83	35.58	30.50
	Median [Q25-Q75]	1.00 [0.01–9.50]	1.26 [0.01-10]	1.20 [0.01–9.20]

Figure 6. Neosensitizations in the HDM-AIT study group and in the HDM non-AIT control group during 12 months of observation.